IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
26 Setembro 2023 - 9:00AM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, is proud to announce its upcoming Research &
Development Day on Thursday, October 12, 2023. The event will run
from 9:00 a.m. to 12:00 p.m. ET and will be accessible both
virtually and in-person in New York, NY. For in-person and virtual
attendance, please register here. The webcast will also be
available under the “Events and Presentations” section of the
Company’s website at https://investors.in8bio.com.
The event will offer the opportunity to gain Key
Opinion Leader (KOL) insights into IN8bio’s clinical and scientific
programs along with upcoming catalysts. The agenda will feature an
overview of gamma-delta T cells and their differentiation for
cellular therapies, IN8bio’s cutting-edge manufacturing
capabilities, clinical trial design and an overview of the upcoming
data presentations at major medical meetings this fall, including
Society for Immunotherapy of Cancer (SITC), Society for
Neuro-Oncology (SNO) and abstracts submitted for the American
Society of Hematology (ASH).
The feature presentations include IN8bio’s
management team, as well as key oncology thought leaders,
including:
Leo Luznik,
M.D. is a Professor of Oncology at Johns Hopkins Medicine,
renowned for his pioneering contributions to the advancement of
allogeneic blood and marrow transplantation. Dr. Luznik is an
expert in the mechanisms of anti-tumor immunity and graft versus
host disease (GvHD). He is one of the architects of the Hopkins
Protocol, which continues to be a mainstay of haplotransplantation
for the treatment of leukemias, including in the INB-100 clinical
program.
Michael
Bishop, M.D. is the Director of the David and Etta Jonas
Center for Cellular Therapy at the University of Chicago. Dr.
Bishop is a prominent clinical investigator in acute leukemias,
with a focus on improving transplant outcomes and preventing
relapse. He is a faculty member and on the planning committee of
the ASTCT/EBMT Conference on Relapse After Transplant and Cellular
Therapy, and will be highlighting gamma-delta T cells as a clinical
strategy to prevent relapse.
A live webcast of the presentation can be
accessed through the Events and Presentations section of the
Company’s website at https://investors.in8bio.com. Following the
live event, an archived replay of the webcast will be made
available on our website.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of gamma-delta T
cell product candidates for solid and liquid tumors. Gamma-delta T
cells are a specialized population of T cells that possess unique
properties, including the ability to differentiate between healthy
and diseased tissue. IN8bio’s DeltEx platform employs allogeneic,
autologous, iPSC and genetically modified approaches to develop
cell therapies designed to effectively identify and eradicate tumor
cells.
IN8bio is currently conducting two investigator-initiated Phase
1 clinical trials for its lead gamma-delta T cell product
candidates: INB-200 for the treatment of newly diagnosed
glioblastoma and INB-100 for the treatment of patients with
hematologic malignancies undergoing haploidentical hematopoietic
stem cell transplantation. IN8bio is initiating INB-400, a
company-sponsored multi-center Phase 2 clinical trial in newly
diagnosed glioblastoma, which received IND clearance in late 2022.
IN8bio also has a broad portfolio of preclinical programs focused
on addressing other hematological and solid tumor cancers. For more
information about IN8bio and its programs, please visit
www.IN8bio.com.
Company Contact:IN8bio,
Inc.Patrick McCall+ 1 646.600.6GDT (6438)info@IN8bio.com
Investors & Media
Contact:Argot PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
IN8bio (NASDAQ:INAB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024